Who are Resilient Biotics's investors?

Resilient Biotics's investors include Berkeley Catalyst, Fulcrum Global Capital.

How much funding has Resilient Biotics raised?

Resilient Biotics has disclosed $11M raised across 2 rounds.

Where is Resilient Biotics headquartered?

Resilient Biotics is headquartered in Research Triangle Park, US.

Resilient Biotics

Research Triangle Park, US · Founded 2016 · Delaware corporation · 10 employees on LinkedIn · 3 known investors

Find your way into Resilient Biotics

Resilient Biotics uses microbiome genomics and data science to discover and develop non-antibiotic, precision microbial therapeutics derived from commensal microbial communities, aimed at preventing respiratory infectious diseases.

AI & Machine Learning Biotech Healthtech

Founders & leadership

Rachelle GalvinNamed on SEC filing

Christopher BelnapNamed on SEC filing

Greg WernerNamed on SEC filing

Board

Drew Lanza Board directorPartner at Berkeley Catalyst

Eric EasonBoard director

John Peryam Board MemberManaging Partner at Fulcrum Global Capital

Investors · 3

Berkeley Catalystlisted by Berkeley CatalystBerkeley

How we know: the VCSheet dataset · Not right? Tell us

Fulcrum Global Capitallisted by Fulcrum Global CapitalKansas Cityvia John Peryam · board

How we know: board seat on SEC Form D · funding news · Not right? Tell us

Also in the syndicate · 1

Elanco

Reported raises · per SEC filings

Form D private placements

$11M disclosed across 2 rounds · 2020–2022

▶$3.9MraisedDec 2024 · 6 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Eric EasonDirector
John PeryamDirector
Rachelle GalvinExecutive Officer, Director
Drew LanzaDirector
Christopher BelnapExecutive Officer, Director

Offering amount: $4.6M
Amount sold: $3.9M
First sale: Aug 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$7.2MraisedDec 2020 · 18 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Christopher BelnapExecutive Officer, Director
Eric EasonDirector
John PeryamDirector
Greg WernerExecutive Officer, Director

Offering amount: $7.2M
Amount sold: $7.2M
First sale: Dec 2020
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

MicrobioticaMicrobiotica is a clinical-stage biopharmaceutical company developing precision live biotherapeutic products derived from the human microbiome for immuno-oncology and inflammatory bowel disease. The company uses a proprietary microbiome profiling platform based on clinical data to identify specific bacterial strains associated with patient benefit.

ResilienceResilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.

Companies working in the same space as Resilient Biotics.

In the news

Management Team - Resilient Bioticsresilientbiotics.com · Jun 2021

Frequently asked questions

What does Resilient Biotics do?: Resilient Biotics uses microbiome genomics and data science to discover and develop non-antibiotic, precision microbial therapeutics derived from commensal microbial communities, aimed at preventing respiratory infectious diseases.
Who are Resilient Biotics's investors?: Resilient Biotics's investors include Berkeley Catalyst, Fulcrum Global Capital.
How much funding has Resilient Biotics raised?: Resilient Biotics has disclosed $11M raised across 2 rounds.
Where is Resilient Biotics headquartered?: Resilient Biotics is headquartered in Research Triangle Park, US.